In R/R MCL, efficacy may come with trade-offs1

Treatment options have historically been limited

Doctor wearing stethoscope icon

Patients with MCL may relapse or become refractory after some available therapies1,2

Prescriptions icon

Response to therapy may continue to decline with subsequent lines of treatment3

Continuous therapy cycle icon

Most existing therapies still carry the burden of continuous treatment1

Three patients icon

Patients may be excluded from certain treatments, such as CAR T, due to tolerability concerns1,2

  • CAR T has different eligibility criteria than transplant
  • Patients with R/R MCL can potentially benefit from CAR T therapy


A powerful option with broad eligibility in R/R MCL is needed

CAR, chimeric antigen receptor; MCL, mantle cell lymphoma; R/R, relapsed or refractory.

This website is best viewed
using the horizontal display on
your tablet device.

This website is best viewed
using the vertical display on
your mobile device.

  1. Burkart M, Karmali R. Relapsed/refractory mantle cell lymphoma: beyond BTK inhibitors. J Pers Med. 2022;12(3):376. doi:0.3390/jpm12030376
  2. Armitage JO, Longo DL. Mantle-cell lymphoma. N Eng J Med. 2022;386(26):2495-2506. doi:10.1056/NEJMra2202672
  3. Kumar A, Sha F, Toure A, et al. Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse. Blood Cancer J. 2019;9(6):50. doi:10.1038/41408-019-0209-5